A detailed history of Morgan Stanley transactions in Sight Sciences, Inc. stock. As of the latest transaction made, Morgan Stanley holds 157,051 shares of SGHT stock, worth $967,434. This represents 0.0% of its overall portfolio holdings.

Number of Shares
157,051
Previous 196,979 20.27%
Holding current value
$967,434
Previous $1.02 Million 18.41%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$4.02 - $5.89 $160,510 - $235,175
-39,928 Reduced 20.27%
157,051 $829,000
Q4 2023

Feb 13, 2024

BUY
$1.29 - $5.86 $47,606 - $216,257
36,904 Added 23.05%
196,979 $1.02 Million
Q3 2023

Nov 15, 2023

SELL
$2.88 - $8.8 $1.38 Million - $4.21 Million
-478,208 Reduced 74.92%
160,075 $539,000
Q2 2023

Aug 14, 2023

SELL
$7.46 - $10.67 $14,711 - $21,041
-1,972 Reduced 0.31%
638,283 $5.28 Million
Q1 2023

May 15, 2023

SELL
$8.44 - $13.35 $514,384 - $813,629
-60,946 Reduced 8.69%
640,255 $5.6 Million
Q4 2022

Feb 14, 2023

BUY
$5.58 - $13.94 $658 - $1,644
118 Added 0.02%
701,201 $8.56 Million
Q3 2022

Nov 14, 2022

BUY
$6.1 - $11.41 $2.83 Million - $5.29 Million
463,240 Added 194.77%
701,083 $4.45 Million
Q2 2022

Oct 27, 2022

BUY
$6.61 - $11.99 $987,904 - $1.79 Million
149,456 Added 169.09%
237,843 $2.14 Million
Q2 2022

Aug 15, 2022

BUY
$6.61 - $11.99 $987,904 - $1.79 Million
149,456 Added 169.09%
237,843 $2.14 Million
Q1 2022

Oct 27, 2022

SELL
$11.56 - $17.9 $1.73 Million - $2.68 Million
-149,456 Reduced 62.84%
88,387 $1.02 Million
Q1 2022

May 13, 2022

BUY
$11.56 - $17.9 $270,457 - $418,788
23,396 Added 36.0%
88,387 $1.02 Million
Q4 2021

Feb 14, 2022

BUY
$17.36 - $27.36 $1.08 Million - $1.69 Million
61,942 Added 2031.55%
64,991 $1.14 Million
Q3 2021

Nov 15, 2021

BUY
$22.34 - $39.1 $68,114 - $119,215
3,049 New
3,049 $69,000

Others Institutions Holding SGHT

About Sight Sciences, Inc.


  • Ticker SGHT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 47,826,200
  • Market Cap $295M
  • Description
  • Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; a...
More about SGHT
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.